GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » ROA %

Constellation Pharmaceuticals (Constellation Pharmaceuticals) ROA % : -37.96% (As of Mar. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Constellation Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2021 was $-160.29 Mil. Constellation Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2021 was $422.26 Mil. Therefore, Constellation Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2021 was -37.96%.

The historical rank and industry rank for Constellation Pharmaceuticals's ROA % or its related term are showing as below:

CNST' s ROA % Range Over the Past 10 Years
Min: -122.4   Med: -86.82   Max: -30.05
Current: -31.22

During the past 5 years, Constellation Pharmaceuticals's highest ROA % was -30.05%. The lowest was -122.40%. And the median was -86.82%.

CNST's ROA % is not ranked
in the Biotechnology industry.
Industry Median: -35.15 vs CNST: -31.22

Constellation Pharmaceuticals ROA % Historical Data

The historical data trend for Constellation Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals ROA % Chart

Constellation Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
ROA %
-89.22 -122.40 -86.82 -33.03 -30.05

Constellation Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.36 -26.22 -25.98 -31.57 -37.96

Competitive Comparison of Constellation Pharmaceuticals's ROA %

For the Biotechnology subindustry, Constellation Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Constellation Pharmaceuticals's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's ROA % falls into.



Constellation Pharmaceuticals ROA % Calculation

Constellation Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2020 is calculated as:

ROA %=Net Income (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=-126.357/( (399.13+441.854)/ 2 )
=-126.357/420.492
=-30.05 %

Constellation Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2021 is calculated as:

ROA %=Net Income (Q: Mar. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Mar. 2021 ))/ count )
=-160.288/( (441.854+402.659)/ 2 )
=-160.288/422.2565
=-37.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2021) net income data. ROA % is displayed in the 30-year financial page.


Constellation Pharmaceuticals  (NAS:CNST) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2021 )
=Net Income/Total Assets
=-160.288/422.2565
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-160.288 / 0)*(0 / 422.2565)
=Net Margin %*Asset Turnover
=N/A %*0
=-37.96 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Constellation Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
215 First Street, Suite 200, Cambridge, MA, USA, 02142
Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.
Executives
Emma Reeve officer: Chief Financial Officer C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine officer: See Remarks C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith director, 10 percent owner 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey officer: Chief Medical Officer C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia director 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha director, officer: See Remarks C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer officer: Chief Scientific Officer 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Headlines